Your session is about to expire
← Back to Search
Isatuximab + Lenalidomide for Multiple Myeloma
Study Summary
This trial will test if isatuximab, with lenalidomide, can help treat highrisk multiple myeloma post-stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood counts need to meet certain requirements.I am between 18 and 70 years old with newly diagnosed myeloma.You must have a detectable disease as defined by specific criteria when you are diagnosed.I can communicate in English or another language.I have allergies to drugs similar to the ones used in this study.My myeloma is classified as high-risk.I do not have any uncontrolled illnesses.I can care for myself but may not be able to do active work.My major organs are functioning well.I have not had major surgery in the last 4 weeks.I agree to use birth control and not donate sperm.My myeloma worsened before starting maintenance treatment.I am currently being treated for an infection.You have had a severe allergic reaction or skin rash to certain medications.My cancer responded well to initial treatments.I am not pregnant or breastfeeding and will follow the birth control requirements.I had a stem cell transplant with the right preparation and my cell counts recovered.I am HIV-positive or have active hepatitis A, B, or C.
- Group 1: isatuximab plus lenalidomide after an autologous stem cell transplantation (ASCT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is eligibility for this clinical study confined to adults, or are minors also allowed to participate?
"The parameters for enrolment into this clinical trial state that the minimum age is 18 and no more than 70 years old."
Are there opportunities for individuals to join this research endeavor?
"Evidently, this clinical research is currently not seeking participants as the last update was on March 8th of 2023. Initially posted in September 30th 2023, there are presently 810 other studies actively enrolling patients."
Who is able to sign up for the research protocol?
"This medical trial seeks 61 individuals with multiple myeloma aged between 18 and 70."
Has the FDA accorded its blessing to isatuximab combined with lenalidomide post-autologous stem cell transplantation?
"Our experts at Power assessed the safety of isatuximab plus lenalidomide after an autologous stem cell transplantation to be a 2 on a scale from 1-3. This decision was based off the Phase 2 trial data, which confirms safety but does not yet prove efficacy."
Share this study with friends
Copy Link
Messenger